Kurs & Likviditet
Beskrivning
Land | Danmark |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Hørsholm, Denmark, June 24, 2021 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") hereby announces that Pareto Securities AS has published an equity research initiation report on ExpreS2ion. They initate coverage with a Buy rating and a target price of 60 SEK per share.
The major contributors of value in the sum-of-the-parts valuation are ExpreS[2]ion's 34% stake in its joint venture with NextGen Vaccines, AdaptVac, ExpreS[2]ion's breast cancer vaccine candidate, ES2B-C001 HER2-cVLP, the company's Influenza program as part of the INDIGO consortium, and royalties from the PREVENT-nCoV COVID-19 vaccine program.
The full English version of the company-sponsored equity research report is attached to this press release.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se